dmd bull thesi strengthen sinc feb monthli
updat competitor report underwhelm initi data dmd
gene tx program elsewher disclos high dose dmd gene
tx trial vg/kg may step event
safeti issu clear increment updat reflect cautiou
develop approach result issu follow dose first
patient higher dose latest updat come heel
last month set initi data updat timelin program
earli result grow increasingli
comfort srpt dmd program may prove first-in-class
well best-in-class see two critic catalyst drive share
appreci
complet srpt
manufactur scale-up allow commenc confirmatori
trial late initi data expect
may allevi competit uncertainti around srpt program
next month
boost srpt stori discuss preview
note initi data fail deliv major move share
though believ result establish poc lgmd
provid base expect valu built time recent
pullback allow investor particip opportun without
pay think regulatori commerci work remain
face nt competit lgmd clearli possess expertis
necessari tackl develop challeng also see solidifi
lgmd platform enhanc srpt attract
increas tp reflect chang po
lgmd program increas lt market share
dmd gt program ep vs old risk
thesi includ clinic regulatori commerci headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
sarepta biotechnolog compani focus develop
rna-target therapeut compani primarili focus
price rate outperform target price analyst tin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario reflect probabl success
dmd gene therapi market share
dmd gene therapi probabl success
gene therapi probabl success
lgmd platform probabl success
casimersen golodirsen
grey sky scenario reflect valu dmd gene
therapi valu lgmd gene therapi premium
dmd gene therapi timelin sarepta remain
lead
dmd gene therapi three-hors race right sarepta solid
clinic studi due substanti preval market opportun estim may
exceed first-mov advantag expect play critic role determin
respect program valu review recent develop program
continu see sarepta lead
figur appear month lead competitor
sarepta dmd gene therapi program appear lead
compani report promis interim result patient studi octob
recent announc commenc trial follow meet
fda expect studi random double-blind
placebo-control studi patient age year old clinicaltri gov list
primari outcom measur drug safeti profil chang
microdystrophin express baselin week addit compani report
includ comparison chang function endpoint versu placebo week
support potenti approv figur overview trial design key
differ rel trial
expect trial enrol quickli compani guid enrol
complet sarepta report patient dose trial
februari particularli impress given start date trial
decemb trial conduct one site compani report
screen-failur rate well line expect
number
patient initi studi
origin plan month old patient
mutat exon
previou treatment steroid month yr old
stabl steroid least wk yr old
sign cardiomyopathi includ echocardiogram eject
fraction
subject antibodi titer
chang micro-dystrophin express pre vs post treatment
decreas ck
time go
ascend descend step
cardiac mri
random double-blind placebo-control trial
establish clinic diagnosi dmd document dystrophin gene
mutat dmd phenotyp
indic symptomat muscular dystrophi protocol-specifi
stabl steroid least wk
impair cardiovascular function
abnorm liver renal function protocol-specifi criteria
exposur anoth investig drug exon skip medic
function data
chang baselin quantiti microdystrophin protein express
compani plan provid updat program
patient dose late februari dose expect
complet
manufactur like rate-limit factor term quickli sarepta move
toward approv addit trial previous outlin fda requir
confirmatori trial use commerci scale materi support approv sarepta
expect complet manufactur scale-up allow confirmatori trial start
later year
exact design second trial still discuss fda project fda
file may base biopsi demonstr compar commerci
scale product clinic materi use previou trial
confid potenti approv path support experi
file occur base prelim earli data hand patient
commerci product supplement long-term function data patient treat
clinic suppli materi
compar first trial confirmatori trial
enrol patient intern confirmatori trial enrol
patient current trial estim may includ patient
exact number patient confirmatori trial hasnt disclos
expect trial enrol rapidli note larger size vs first trial
off-set increas number trial site
may includ broader patient popul balanc year
expect begin outlin expans strategi first trial
patient year old older younger patient may benefit therapi
think compani may incorpor multipl cohort explor broader
patient popul confirmatori trial potenti trial allow
broadest possibl label
continu believ sarepta month lead
februari report treat patient believ
low dose vg/kg high dose vg/kg plan enrol
patient high dose cohort expect trial fulli enrol soon exact
stagger unclear timelin could shift slightli initi biopsi result
figur pfizer dmd durat follow-up present mid-feb
pfizer commentari dose part februari updat may suggest
emerg neg differenti program specif first time pfizer
disclos potenti mid-dos vg/kg event dose limit toxic
dose new disclosur may due abund
caution could suggest see issu elev immun
respons associ treatment use higher dose disclosur come
heel
immun respons program solid abeona avexi
use gene therapi program disclos
degre platelet declin follow treatment declin platelet may
indic immun respons treatment report instanc
event rel minor immun respons lead sae
solid program requir use soliri solid suggest effect may
relat use believ manag issu though enough
data exist consid hypothet
potenti timelin chang compani previous shift timelin
initi trial result compani sinc state
data could earli
look forward believ compani could initi pivot trial end
earli assumpt calcul includ
biopsi data patient new high dose
assum one month interv dose first patient high dose
point pace enrol may speed
end-of-phas meet like request base
result high dose
disclos statu manufactur scale-up believ
compani make effort regard time better-than-expect
scale-up timelin seem possibl process scale time pivot trial
commenc believ pfizer product could market
month behind sarepta project timelin meanwhil scale-up conduct
crossov arm util separ trial use commerci materi
requir could month behind sarepta
solid shaki ground
investor speak continu see like greater competit threat
sarepta compar solid februari solid report underwhelm initi data
patient dose dmd gene therapi program base
month biopsi patient microdystrophin express normal
patient microdystrophin express undetect via western blot compani
provid addit detail drug safeti profil recal compani
previous disclos sae first patient resolv via use soliri
led protocol chang includ use soliri manag immun respons
appear next patient also requir soliri
look ahead solid plan dose escal expect dose advanc
origin dose vg/kg consist dose solid preclin model
howev solid involv irb fda need
chang trial protocol exist protocol requir patient treat prior
dose escal expect process could fairli quick navig may allow
dose patient soon potenti biopsi result higher dose
cohort ye ahead compani exhaust current cash runway
project spend level
given recent event believ solid least month behind
littl evid like competit product insuffici cash balanc like elong
manufactur scale timelin may delay time dose patient
updat strengthen bull thesi
late februari report suggest initi data first patient
gene therapi program patient receiv dose vg/kg patient
follow-up rang month month highlight includ
mean beta-sarcoglycan express day narrow rang
baselin protein express provid context doctor
spoken believ express convey clinic benefit
like need valid evid function improv
posit beta-sarcoglycan posit fiber express rang
ck level improv mean baselin u/l
exceed expect improv strongli suggest
safeti profil therapi gener well toler reason context
diseas burden declin platelet count patient
transient nausea patient lft elev one includ
bilirubin elev consid sae sae occur steroid
taper resolv follow resum steroid use lead protocol chang
around steroid move forward includ steroid administr day post-
dose day
compani plan present addit data mda meet april
abstract embargo april present larg consist
previous disclos inform present baselin characterist
patient includ baselin beta-sarcoglycan express expect minim
expect function data could avail late base fact studi
dmd gener requir month year see clear function improv rel
natur histori note natur histori dmd much better defin compar
yet commit forum provid initi function
data studi
look ahead plan meet fda come month defin path
forward includ whether dose escal potenti regulatori
strategi lgmd program event compani dose escal biopsi
data high dose cohort could avail year end time think
potenti registr trial could commenc
increas valu
base srpt februari updat feel increment confid program
increas probabl success po
srpt microdystrophin program dcf attribut program
lgmd indic
lgmd preval includ diseas
subtyp pegoraro et al sarepta explor uniqu gene therapi
treatment collect lgmd subtyp
account popul figur background individu
subtyp explor
figur background lgmd subtyp
predictor diseas sever
first decad life
loss compon
loss ambul usual decad life
often mark progress acut ill
patient may weaken heart muscl cardiac impair
patient sveen ml et al semplicini et al
patient live rel long
live
estim rang
per million
common amish
correl sgcb gene
mutat sarcoglycan protein
first decad life
loss compon
loss ambul decad life fayssoil et al
one studi patient respiratori event year period
home mechan ventil decad life
death decad life
death
decad life
first decad life
loss compon
loss ambul decad life
greater heart involv fayssoil et al
one studi patient respiratori event year period
home mechan ventil decad life
death decad life
death
decad life
estim rang
per million
mutat puerto rican less
sever subtyp al-zaidi
caus dysf gene
may absent
muscl repair
slower progress sarcoglycanopathi
leg gener first affect
loss ambul
associ cardiomyopathi respiratori issu
one
along
million common
jewish popul
possibl degre remain
establish
anoctamin other
protein
initi symptom includ weak wast lower limb
patient remain ambul late adulthood
respiratori heart problem rare
femal often less sever afflict male
one
per million
possibl degre remain
compani data credit suiss estim wohproject org univers exet orphanet fayssoil et al jain foundat musculardystrophyuk org genereview
believ patient us patient
estim patient yr old ambulatori line
popul studi clinic trial possibl nonambulatori
patient could see benefit improv cardiac respiratori function
sure whether clinician would seek treat patient initi commerci
reimburs pictur may look like absenc data
see littl way competit threat lgmd littl drug discoveri work
done lgmd histor awar gene therapi develop
lgmd therapi clinic atyr pharma resolari shorten
variant protein resokin
expect may gener peak sale recur revenu
preval satur figur revenu
rate antibodi
preval elig gt
year ent share yr peak
rate antibodi
preval elig gt
year ent share yr peak
pay perform net cost
rate antibodi
preval elig gt
year ent share yr peak
pay perform net cost
posit result support increas convict broader lgmd
multipl common across srpt broader lgmd platform program
allow deliveri full length replac gene capsid use
program sever program use promot
program demonstr preclin efficaci shown
earli sign activ isol limb studi furthermor sarepta favor
posit commerci competitor pursu indic
competitor awar approach clinic studi gene therapi
figur detail lgmd program
figur srpt lgmd develop program upcom catalyst
preclin safeti dose-
data expect mda
meet april
expect enter iv
updat time move
studi
clinic expect
updat time move
expect
updat time move
clinic expect
explicitli model lgmd program besid togeth see
four addit lgmd program potenti support annual
recur revenu opportun price compar dmd gene therapi program
increas valu remain lgmd program valuat
determin use dmd valu compar basic assumpt includ
four lgmd program develop address dmd
owe uncertain natur histori assum lgmd program achiev
rel penetr respect target market compar dmd
variant lgmd studi notabl less sever dmd
assign po reflect limit clinic data
complex need achiev success four distinct program
technic risk dual vector approach off-set initi
derisk aav capsid promot gener
use on-going dmd studi along derisk support
earli sign clinic success
assum hold monopoli posit target lgmd market
forese futur
specif npv four lgmd exclud
repres approxim dcf-driven target price
compani mention price
